# A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

> **NCT02636842** · PHASE1 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Aripiprazole Lauroxil

## Key facts

- **NCT ID:** NCT02636842
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2016-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02636842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02636842, "A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02636842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*